Poolbeg Pharma, a clinical-stage biopharmaceutical company focused on cancer immunotherapy, has appointed Adrian Kilcoyne to its Scientific Advisory Board.
Bringing over 20 years of experience with strategic drug development leadership to the role, Kilcoyne is currently Chief Medical Officer (CMO) at Cellectis, focusing on the development of allogenic CAR-T therapies.
Other former roles include CMO at Humanigen, where he helped to build the immunology and oncology portfolios, and multiple senior leadership roles at several pharmaceutical and biotechnology companies, including AstraZeneca, Celgene, Sanofi, Roche and Eli Lilly.
Luke O’Neill, Chair of the Scientific Advisory Board of Poolbeg Pharma, said: “Adrian brings a wealth of experience in oncology and cell therapy drug development, combined with deep clinical insight and regulatory expertise that will be invaluable to us as we progress POLB 001 through the TOPICAL trial, with the ultimate aim of transforming cancer care for patients and healthcare systems.”
Adrian Kilcoyne, Scientific Advisory Board Member of Poolbeg Pharma, said: “Having seen first-hand both the clinical impact on patients and the economic burden on healthcare systems posed by immunotherapy related CRS, I believe POLB 001 has the potential to transform the patient experience.
“The prevention of CRS remains a significant unmet need and addressing it may enable access for a greater number of patients to life-saving immunotherapies.”